The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Benign Prostatic Hyperplasia Treatment Market Research Report 2025

Global Benign Prostatic Hyperplasia Treatment Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1719999

No of Pages : 95

Ask Your Query
Synopsis
The global Benign Prostatic Hyperplasia Treatment market was valued at US$ 6476.6 million in 2023 and is anticipated to reach US$ 8438.6 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia Treatment.
Report Scope
The Benign Prostatic Hyperplasia Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott
Allergan plc
Astellas Pharma
Asahi Kasei Corporation
Boehringer Ingelheim GmbH
GlaxoSmithKline
Pfizer
Sanofi
Teva Pharmaceutical Industries
Merck
Boston Scientific Corporation
Teleflex Incorporated
Endo International
Urologix
LISA Laser
Olympus
Segment by Type
Drug Class
Minimally Invasive Surgeries
Laser Therapy
Others
Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Benign Prostatic Hyperplasia Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Drug Class
1.2.3 Minimally Invasive Surgeries
1.2.4 Laser Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia Treatment Market Perspective (2019-2030)
2.2 Benign Prostatic Hyperplasia Treatment Growth Trends by Region
2.2.1 Global Benign Prostatic Hyperplasia Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Benign Prostatic Hyperplasia Treatment Historic Market Size by Region (2019-2024)
2.2.3 Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Region (2025-2030)
2.3 Benign Prostatic Hyperplasia Treatment Market Dynamics
2.3.1 Benign Prostatic Hyperplasia Treatment Industry Trends
2.3.2 Benign Prostatic Hyperplasia Treatment Market Drivers
2.3.3 Benign Prostatic Hyperplasia Treatment Market Challenges
2.3.4 Benign Prostatic Hyperplasia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia Treatment Players by Revenue
3.1.1 Global Top Benign Prostatic Hyperplasia Treatment Players by Revenue (2019-2024)
3.1.2 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Benign Prostatic Hyperplasia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Treatment Revenue
3.4 Global Benign Prostatic Hyperplasia Treatment Market Concentration Ratio
3.4.1 Global Benign Prostatic Hyperplasia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Treatment Revenue in 2023
3.5 Benign Prostatic Hyperplasia Treatment Key Players Head office and Area Served
3.6 Key Players Benign Prostatic Hyperplasia Treatment Product Solution and Service
3.7 Date of Enter into Benign Prostatic Hyperplasia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Benign Prostatic Hyperplasia Treatment Breakdown Data by Type
4.1 Global Benign Prostatic Hyperplasia Treatment Historic Market Size by Type (2019-2024)
4.2 Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Type (2025-2030)
5 Benign Prostatic Hyperplasia Treatment Breakdown Data by Application
5.1 Global Benign Prostatic Hyperplasia Treatment Historic Market Size by Application (2019-2024)
5.2 Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Benign Prostatic Hyperplasia Treatment Market Size (2019-2030)
6.2 North America Benign Prostatic Hyperplasia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2019-2024)
6.4 North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Treatment Market Size (2019-2030)
7.2 Europe Benign Prostatic Hyperplasia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2019-2024)
7.4 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size (2019-2030)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size (2019-2030)
9.2 Latin America Benign Prostatic Hyperplasia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2019-2024)
9.4 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (2019-2030)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Detail
11.1.2 Abbott Business Overview
11.1.3 Abbott Benign Prostatic Hyperplasia Treatment Introduction
11.1.4 Abbott Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.1.5 Abbott Recent Development
11.2 Allergan plc
11.2.1 Allergan plc Company Detail
11.2.2 Allergan plc Business Overview
11.2.3 Allergan plc Benign Prostatic Hyperplasia Treatment Introduction
11.2.4 Allergan plc Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.2.5 Allergan plc Recent Development
11.3 Astellas Pharma
11.3.1 Astellas Pharma Company Detail
11.3.2 Astellas Pharma Business Overview
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Treatment Introduction
11.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.3.5 Astellas Pharma Recent Development
11.4 Asahi Kasei Corporation
11.4.1 Asahi Kasei Corporation Company Detail
11.4.2 Asahi Kasei Corporation Business Overview
11.4.3 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Introduction
11.4.4 Asahi Kasei Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.4.5 Asahi Kasei Corporation Recent Development
11.5 Boehringer Ingelheim GmbH
11.5.1 Boehringer Ingelheim GmbH Company Detail
11.5.2 Boehringer Ingelheim GmbH Business Overview
11.5.3 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Introduction
11.5.4 Boehringer Ingelheim GmbH Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.5.5 Boehringer Ingelheim GmbH Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Detail
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Introduction
11.6.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.6.5 GlaxoSmithKline Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Benign Prostatic Hyperplasia Treatment Introduction
11.7.4 Pfizer Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Benign Prostatic Hyperplasia Treatment Introduction
11.8.4 Sanofi Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.8.5 Sanofi Recent Development
11.9 Teva Pharmaceutical Industries
11.9.1 Teva Pharmaceutical Industries Company Detail
11.9.2 Teva Pharmaceutical Industries Business Overview
11.9.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Introduction
11.9.4 Teva Pharmaceutical Industries Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.9.5 Teva Pharmaceutical Industries Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Benign Prostatic Hyperplasia Treatment Introduction
11.10.4 Merck Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.10.5 Merck Recent Development
11.11 Boston Scientific Corporation
11.11.1 Boston Scientific Corporation Company Detail
11.11.2 Boston Scientific Corporation Business Overview
11.11.3 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Introduction
11.11.4 Boston Scientific Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.11.5 Boston Scientific Corporation Recent Development
11.12 Teleflex Incorporated
11.12.1 Teleflex Incorporated Company Detail
11.12.2 Teleflex Incorporated Business Overview
11.12.3 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Introduction
11.12.4 Teleflex Incorporated Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.12.5 Teleflex Incorporated Recent Development
11.13 Endo International
11.13.1 Endo International Company Detail
11.13.2 Endo International Business Overview
11.13.3 Endo International Benign Prostatic Hyperplasia Treatment Introduction
11.13.4 Endo International Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.13.5 Endo International Recent Development
11.14 Urologix
11.14.1 Urologix Company Detail
11.14.2 Urologix Business Overview
11.14.3 Urologix Benign Prostatic Hyperplasia Treatment Introduction
11.14.4 Urologix Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.14.5 Urologix Recent Development
11.15 LISA Laser
11.15.1 LISA Laser Company Detail
11.15.2 LISA Laser Business Overview
11.15.3 LISA Laser Benign Prostatic Hyperplasia Treatment Introduction
11.15.4 LISA Laser Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.15.5 LISA Laser Recent Development
11.16 Olympus
11.16.1 Olympus Company Detail
11.16.2 Olympus Business Overview
11.16.3 Olympus Benign Prostatic Hyperplasia Treatment Introduction
11.16.4 Olympus Revenue in Benign Prostatic Hyperplasia Treatment Business (2019-2024)
11.16.5 Olympus Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock